FBIO · Categories · M&A
FBIO - Mergers and acquisitions
Fortress Biotech Inc. (FBIO) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for FBIO
- Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition expands Journey Medical's portfolio to nine marketed dermatology products East West Bank Credit agreement expanded to $30.0 million SCOTTSDALE, Ariz., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that the company entered into a definitive agreement with VYN
- Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes DiseaseSentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the third quarter of 2021 and to be completed during the fourth quarter of 2021 NEW YORK and SOLANA BEACH, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, and Sentynl Therapeutics, Inc. (“Sentynl”), a